Clinical Trial

Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)

Study acronym: CTONG 2508
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, prospective, open-label Phase II study designed to evaluate the safety and efficacy of adjuvant sintilimab therapy guided by minimal residual disease (MRD) in patients with Stage II-IIIB non-small cell lung cancer (NSCLC) who have not achieved a pathological complete response (non-pCR) after neoadjuvant immunotherapy combined with chemotherapy. The study is being conducted at the Third People's Hospital of Chengdu and the Guangdong Provincial People's Hospital.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-06.
Status change: Not Yet Recruiting → Recruiting 2025-12-30
Trial Details
NCT Number NCT07120698
Lead Sponsor Guangdong Association of Clinical Trials
Collaborators: Zunyi Medical College, Suining Central Hospital, Shenzhen Second People's Hospital, Guangdong Provincial People's Hospital
Conditions NSCLC (Non-small Cell Lung Cancer), MRD, II-IIIB Stages, Adjuvant Immunotherapy
Enrollment 115 participants
Start Date 2025-11-05
Primary Completion 2029-06-26 (estimated)
Study Completion 2029-07-26 (estimated)
Updated on ClinicalTrials.gov 2026-01-05